Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GENinCodeSTU:9PL -4.55% 3-Year EBITDA Growth Rate is 29.90% as of Dec. 2025, which is at its 10-year median of 29.90. The stock has 4 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, GENinCode ranks better than 73.05% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 29.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 0.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of GENinCode was 30.70% per year. The lowest was -84.40% per year. And the median was 29.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
GENinCode 3-Year EBITDA Growth Rate Related Terms
STU:9PL vs TMO, DHR, NTRA: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, GENinCode's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GENinCode 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GENinCode's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where GENinCode's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 29.90% mean?
GENinCode (STU:9PL) has a 3-Year EBITDA Growth Rate of 29.90% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for GENinCode and its competitors. This is near median its historical median of 29.90. According to the industry distribution chart, GENinCode ranks #45 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 26.9%.
Is GENinCode's 3-Year EBITDA Growth Rate too high?
GENinCode's current 3-Year EBITDA Growth Rate of 29.90% is near median its 10-year median of 29.90. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.00. GENinCode's value of 29.90% is 171.8% above this industry median. Based on the distribution chart, GENinCode ranks #45 out of 167 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does GENinCode's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, GENinCode ranks #45 out of 167 companies for 3-Year EBITDA Growth Rate. This puts GENinCode in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.00. GENinCode's value of 29.90% is 171.8% above this benchmark. While the company's 10-year median is 29.90 vs. the industry median of 11.00, GENinCode has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.00, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GENinCode's current 3-Year EBITDA Growth Rate of 29.90% is 171.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for GENinCode and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GENinCode's current 3-Year EBITDA Growth Rate is 29.90%, which is near median its own 10-year median of 29.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GENinCode stock overvalued right now?
GENinCode (STU:9PL) has a current 3-Year EBITDA Growth Rate of 29.90%. The stock's GF Value™ is €0.04, compared to a current price of €0.01 — trading 73.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 29.90%, which is near median its 10-year median of 29.90 and 171.8% above the Medical Diagnostics & Research industry median of 11.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For GENinCode (STU:9PL), the current 3-Year EBITDA Growth Rate is 29.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GENinCode PLC principal activity is the development and commercialisation of clinical genetic tests, to provide predictive analysis of risk to a patient's health based on their genes. The company has one operating segment. The company has presence in Spain, UK, United States, Italy, Germany, and Rest of World. The company generates majority of revenue from Spain. Its commercial products are CE-Marked, with CARDIO inCode, THROMBO inCode, and LIPID inCode.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:9PL has been successfully added to your 
